VEKLURY (remdesivir)
COVID-19 (SARS-COV-2) ANTIVIRAL AGENTS-NUCLEOTIDE ANALOG · COVID-19
GILEAD SCIENCES
Drug class
COVID-19 (SARS-CoV-2) Antiviral Agents
COVID-19 (SARS-CoV-2) antiviral agents constitute a functional therapeutic class of direct-acting antimicrobial drugs designed to treat infection caused by the severe acute respiratory syndrome coronavirus 2. Read more about COVID-19 (SARS-CoV-2) Antiviral Agents
4 drugs in this class 4 manufacturers
Drugs in COVID-19 (SARS-CoV-2) Antiviral Agents
LAGEVRIO (EUA) (molnupiravir)
COVID-19 (SARS-COV-2) ANTIVIRAL AGENTS-NUCLEOTIDE ANALOG
Merck Sharp & Dohme
PAXLOVID (nirmatrelvir/ritonavir)
COVID-19 (SARS-COV-2) ANTIVIRAL-MAIN PROTEASE INHIBITORS · COVID-19
Laboratories Div
XOCOVA (ensitrelvir fumarate)
COVID-19 (SARS-COV-2) ANTIVIRAL-MAIN PROTEASE INHIBITORS · COVID-19 POST-EXPOSURE PREVENTION
SHIONOGI PHARMA
Filter & compare in the drug finder →
Opens the drug finder with COVID-19 (SARS-CoV-2) Antiviral Agents preselected. Add indication or manufacturer filters there.
COVID-19 (SARS-CoV-2) antiviral agents constitute a functional therapeutic class of direct-acting antimicrobial drugs designed to treat infection caused by the severe acute respiratory syndrome coronavirus 2.
These medications exert their therapeutic role by selectively disrupting essential stages of viral replication, primarily through the inhibition of viral proteases such as the 3C-like protease or the termination of viral RNA synthesis via RNA-dependent RNA polymerase inhibition.
Clinically, these agents are utilized to manage acute COVID-19, functioning to accelerate clinical recovery and substantially reduce the risks of disease progression, hospitalization, and death in both outpatient and hospitalized populations at high risk for severe illness.
-
nih.gov
COVID-19 (SARS-CoV-2) antiviral agents constitute a functional therapeutic class of direct-acting antimicrobial drugs designed to treat infection caused by the severe acute respiratory syndrome coronavirus 2
-
nih.gov
COVID-19 (SARS-CoV-2) antiviral agents constitute a functional therapeutic class of direct-acting antimicrobial drugs designed to treat infection caused by the severe acute respiratory syndrome coronavirus 2 Clinically, these agents are utilized to manage acute COVID-19, functioning to accelerate clinical recovery and substantially reduce the risks of disease progression, hospitalization, and death in both outpatient and hospitalized populations at high risk for severe illness
-
nih.gov
These medications exert their therapeutic role by selectively disrupting essential stages of viral replication, primarily through the inhibition of viral proteases such as the 3C-like protease or the termination of viral RNA synthesis via RNA-dependent RNA polymerase inhibition
-
nih.gov
These medications exert their therapeutic role by selectively disrupting essential stages of viral replication, primarily through the inhibition of viral proteases such as the 3C-like protease or the termination of viral RNA synthesis via RNA-dependent RNA polymerase inhibition
-
nih.gov
These medications exert their therapeutic role by selectively disrupting essential stages of viral replication, primarily through the inhibition of viral proteases such as the 3C-like protease or the termination of viral RNA synthesis via RNA-dependent RNA polymerase inhibition
-
fda.gov
Clinically, these agents are utilized to manage acute COVID-19, functioning to accelerate clinical recovery and substantially reduce the risks of disease progression, hospitalization, and death in both outpatient and hospitalized populations at high risk for severe illness
-
nih.gov
Clinically, these agents are utilized to manage acute COVID-19, functioning to accelerate clinical recovery and substantially reduce the risks of disease progression, hospitalization, and death in both outpatient and hospitalized populations at high risk for severe illness
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.